You are here: All Products  > Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront

Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products